Anti-IL-6 therapy may be beneficial for DOCK8-deficient subjects who prove unresponsive to conventional antiviral chemotherapies, indicating a prospective avenue for clinical management of this immunodeficiency. The gene discussed is IL6; the disease is Immunodeficiency.